 Successful reinduction therapy amsacrine cyclocytidine acute nonlymphoblastic leukemia children report Childrens Cancer Study Group Amsacrine AMSA cyclocytidine retrieval therapy pediatric patients acute nonlymphoblastic leukemia ANLL Patients initial remissions relapse Induction therapy intravenous IV AMSA days subcutaneous cyclocytidine days Maintenance therapy IV etoposide days IV AMSA day patients evaluable early deaths Ninety-six patients adequate therapy completion courses therapy patients complete remission Fifteen patients initial induction complete remission Eighteen patients resistant anthracyclines complete responses direct evidence AMSA-induced cardiotoxicity Remission duration days years median days AMSA cyclocytidine effective retrieval therapy patients relapse unresponsive therapy Duration remission short median days